Extending immunosuppressive drug coverage for the lifetime of kidney patients, instead of only covering dialysis, would be a cost-effective way for the federal government to reduce the costs of posttransplant care while improving clinical outcomes for patients.
It is difficult to argue that consumers are maximizing their welfare by consuming trans fats, particularly because the production and taste costs of replacing them do not outweigh the health benefits.
Bias toward allopathic medicine in the research funding and publication of study results makes it difficult for physicians and others to find accurate data about the efficacy of non-Western, nonallopathic treatments.